Proactive Investors
05 Jun 2026, 06:36 UTC · 2h ago
Imaging Biometrics hails trial validation for brain cancer imaging tool
Proactive Investors
05 Jun 2026, 06:36 UTC · 2h ago
Story key points
3 claims · impact-rated
Imaging Biometrics' IB Neuro platform was validated in a US phase II clinical trial as a statistically significant predictor of survival for patients with recurrent glioblastoma. — Clinical validation of a proprietary medical platform in a high-unmet-need area like brain cancer significantly increases the company's commercial value and adoption potential.
+0.70KEFI Gold and Copper PLC has secured a US$20 million equity-ranking royalty, completing the US$340 million funding package for the Tulu Kapi gold project in Ethiopia. — Full funding of a major project removes a significant financing risk and allows the company to move into the execution/production phase.
+0.60Imaging Biometrics intends to commercialize IB Neuro via direct sales and partners targeting the 33 trial centers and global CROs using a capital-efficient strategy that avoids material external funding. — A non-dilutive growth strategy combined with an existing pipeline of trial centers supports a more favorable valuation and lower financial risk.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Ticker attribution
Model heads
The company's IB Neuro platform was validated in a major US clinical trial for predicting survival in brain cancer patients.
The company secured a US$20 million royalty to fully fund its Tulu Kapi gold project and has broken ground.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Newsfile Corp
5h ago
